 |
PDBsum entry 4jzj
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cytokine receptor/immune system
|
PDB id
|
|
|
|
4jzj
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
250 a.a.
|
|
|
|
|
|
|
|
|
|
|
214 a.a.
|
|
|
|
|
|
|
|
|
|
|
219 a.a.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PDB id:
|
|
|
|
| Name: |
|
Cytokine receptor/immune system
|
|
|
Title:
|
|
Crystal structure of receptor-fab complex
|
|
Structure:
|
|
Interleukin-3 receptor subunit alpha. Chain: c, d. Fragment: domain 2, domain 3, unp residues 20-307. Synonym: il-3 receptor subunit alpha, il-3r subunit alpha, il-3r- alpha, il-3ra. Engineered: yes. Mutation: yes. Fab heavy chain. Chain: a, h.
|
|
Source:
|
|
Homo sapiens. Human. Organism_taxid: 9606. Gene: il3ra. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108. Expression_system_cell_line: sf9. Mus musculus. Mouse.
|
|
Resolution:
|
|
|
2.80Å
|
R-factor:
|
0.188
|
R-free:
|
0.244
|
|
|
Authors:
|
|
S.E.Broughton,M.W.Parker
|
|
Key ref:
|
|
S.E.Broughton
et al.
(2014).
Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody.
Cell Rep,
8,
410-419.
PubMed id:
DOI:
|
|
|
Date:
|
|
|
03-Apr-13
|
Release date:
|
09-Apr-14
|
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
|
Headers
|
|
|
|
References
|
|
|
|
|
|
|
|
P26951
(IL3RA_HUMAN) -
Interleukin-3 receptor subunit alpha from Homo sapiens
|
|
|
|
Seq:
Struc:
|
|
|
|
378 a.a.
250 a.a.*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
DOI no:
|
Cell Rep
8:410-419
(2014)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody.
|
|
S.E.Broughton,
T.R.Hercus,
M.P.Hardy,
B.J.McClure,
T.L.Nero,
M.Dottore,
H.Huynh,
H.Braley,
E.F.Barry,
W.L.Kan,
U.Dhagat,
P.Scotney,
D.Hartman,
S.J.Busfield,
C.M.Owczarek,
A.D.Nash,
N.J.Wilson,
M.W.Parker,
A.F.Lopez.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
Interleukin-3 (IL-3) is an activated T cell product that bridges innate and
adaptive immunity and contributes to several immunopathologies. Here, we report
the crystal structure of the IL-3 receptor α chain (IL3Rα) in complex with the
anti-leukemia antibody CSL362 that reveals the N-terminal domain (NTD), a domain
also present in the granulocyte-macrophage colony-stimulating factor (GM-CSF),
IL-5, and IL-13 receptors, adopting unique "open" and classical
"closed" conformations. Although extensive mutational analyses of the
NTD epitope of CSL362 show minor overlap with the IL-3 binding site, CSL362 only
inhibits IL-3 binding to the closed conformation, indicating alternative
mechanisms for blocking IL-3 signaling. Significantly, whereas
"open-like" IL3Rα mutants can simultaneously bind IL-3 and CSL362,
CSL362 still prevents the assembly of a higher-order IL-3 receptor-signaling
complex. The discovery of open forms of cytokine receptors provides the
framework for development of potent antibodies that can achieve a "double
hit" cytokine receptor blockade.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
| |
Links
